Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Buy” by Brokerages

by · The Markets Daily

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus rating of “Buy” by the seventeen ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $32.6667.

Several research firms recently issued reports on DNLI. Wedbush raised their price objective on shares of Denali Therapeutics from $30.00 to $31.00 and gave the stock an “outperform” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. JPMorgan Chase & Co. increased their price objective on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th.

Check Out Our Latest Analysis on DNLI

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $19.96 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The stock’s fifty day moving average is $16.68 and its two-hundred day moving average is $15.14. The firm has a market capitalization of $2.93 billion, a P/E ratio of -6.86 and a beta of 1.11. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $26.18.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the company earned ($0.63) earnings per share. On average, research analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DNLI. Mirae Asset Global Investments Co. Ltd. boosted its stake in Denali Therapeutics by 15.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after buying an additional 753 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Denali Therapeutics by 7.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock worth $189,000 after acquiring an additional 930 shares during the last quarter. E Fund Management Co. Ltd. boosted its position in shares of Denali Therapeutics by 12.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company’s stock worth $190,000 after purchasing an additional 1,543 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its holdings in Denali Therapeutics by 1.3% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 139,663 shares of the company’s stock valued at $2,028,000 after purchasing an additional 1,783 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Featured Articles